DK0955059T3 - Vacciner indeholdende en saponin og en sterol - Google Patents

Vacciner indeholdende en saponin og en sterol

Info

Publication number
DK0955059T3
DK0955059T3 DK99201323T DK99201323T DK0955059T3 DK 0955059 T3 DK0955059 T3 DK 0955059T3 DK 99201323 T DK99201323 T DK 99201323T DK 99201323 T DK99201323 T DK 99201323T DK 0955059 T3 DK0955059 T3 DK 0955059T3
Authority
DK
Denmark
Prior art keywords
sterol
saponin
vaccines containing
vaccines
Prior art date
Application number
DK99201323T
Other languages
Danish (da)
English (en)
Inventor
Martin Friede
Nathalie Marie-Josephe Garcon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0955059(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9508326.7A external-priority patent/GB9508326D0/en
Priority claimed from GBGB9513107.4A external-priority patent/GB9513107D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK0955059T3 publication Critical patent/DK0955059T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK99201323T 1995-04-25 1996-04-01 Vacciner indeholdende en saponin og en sterol DK0955059T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9508326.7A GB9508326D0 (en) 1995-04-25 1995-04-25 Vaccines
GBGB9513107.4A GB9513107D0 (en) 1995-06-28 1995-06-28 Vaccines
PCT/EP1996/001464 WO1996033739A1 (fr) 1995-04-25 1996-04-01 Vaccins contenant une saponine ainsi qu'un sterol

Publications (1)

Publication Number Publication Date
DK0955059T3 true DK0955059T3 (da) 2007-12-17

Family

ID=26306923

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96910019T DK0822831T4 (da) 1995-04-25 1996-04-01 Vacciner indeholdende en saponin og en sterol
DK99201323T DK0955059T3 (da) 1995-04-25 1996-04-01 Vacciner indeholdende en saponin og en sterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK96910019T DK0822831T4 (da) 1995-04-25 1996-04-01 Vacciner indeholdende en saponin og en sterol

Country Status (37)

Country Link
EP (3) EP0884056A1 (fr)
JP (1) JP3901731B2 (fr)
KR (1) KR100463372B1 (fr)
CN (3) CN1111071C (fr)
AP (1) AP771A (fr)
AR (1) AR001686A1 (fr)
AT (2) ATE186842T1 (fr)
AU (2) AU693022B2 (fr)
BG (1) BG63491B1 (fr)
BR (1) BR9608199B1 (fr)
CA (1) CA2217178C (fr)
CY (1) CY2588B2 (fr)
CZ (1) CZ296216B6 (fr)
DE (2) DE69605296T3 (fr)
DK (2) DK0822831T4 (fr)
DZ (1) DZ2026A1 (fr)
EA (1) EA000839B1 (fr)
ES (2) ES2293708T3 (fr)
GR (1) GR3031912T3 (fr)
HK (2) HK1009086A1 (fr)
HU (1) HU227944B1 (fr)
IL (1) IL118004A (fr)
MA (1) MA23850A1 (fr)
MY (1) MY134811A (fr)
NO (1) NO322190B1 (fr)
NZ (1) NZ305365A (fr)
OA (1) OA10629A (fr)
PL (1) PL184061B1 (fr)
PT (1) PT955059E (fr)
RO (1) RO119068B1 (fr)
SA (1) SA96170297B1 (fr)
SI (2) SI0955059T1 (fr)
SK (1) SK282017B6 (fr)
TR (1) TR199701252T1 (fr)
TW (1) TW515715B (fr)
UA (1) UA56132C2 (fr)
WO (1) WO1996033739A1 (fr)

Families Citing this family (490)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
ES2500490T3 (es) * 1997-08-29 2014-09-30 Antigenics Inc. Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (fr) * 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO1999040188A2 (fr) 1998-02-05 1999-08-12 Smithkline Beecham Biologicals S.A. Derives antigenes associes aux tumeurs de la famille mage, et sequences d'acides nucleiques codant ces derives, utilises pour la preparaiton de proteines de fusion et de compositions destinees a la vaccination
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN1629185B (zh) 1998-04-07 2011-11-02 科里克萨公司 结核杆菌抗原融合蛋白及其应用
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US6375952B1 (en) 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PT1126876E (pt) * 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Sistemas adjuvantes e vacinas
JP2002531129A (ja) 1998-12-08 2002-09-24 コリクサ コーポレイション クラミジア感染の処置および診断のための化合物および方法
ATE527360T1 (de) 1998-12-08 2011-10-15 Glaxosmithkline Biolog Sa Neue verbindungen abgeleitet von neisseria meningitidis
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
NZ513935A (en) * 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
EP2163628A3 (fr) 1999-03-12 2010-06-02 GlaxoSmithKline Biologicals S.A. Polypeptides antigéniques de neisseria meningitidis, polynucléotides, et anticorps protecteurs correspondants
EP1880735A3 (fr) * 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccin
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ20013527A3 (cs) 1999-04-02 2002-10-16 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU764969B2 (en) * 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1964573B1 (fr) 1999-10-22 2014-11-26 Aventis Pasteur Limited Procédé d'induction et/ou amélioration d'une réponse immune vers des antigènes de tumeurs
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
AU2243801A (en) * 1999-12-08 2001-06-18 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
DK1265915T3 (da) 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa Nye forbindelser
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
DE60134499D1 (de) * 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
WO2001081379A2 (fr) 2000-04-21 2001-11-01 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
PT2133100E (pt) 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
AU2001273149A1 (en) 2000-06-28 2002-01-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2783274C (fr) 2000-06-29 2018-08-07 Glaxosmithkline Biologicals S.A. Composition de vaccin multivalent a dose reduite d'haemophilus influenza de type b
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
PT2266603E (pt) * 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
WO2002032450A2 (fr) * 2000-10-18 2002-04-25 Glaxosmithkline Biologicals S.A. Vaccins
EP1201250A1 (fr) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
CA2462946C (fr) * 2001-01-26 2014-04-29 Jeffrey A. Lyon Vaccin a base de proteine 142 de merozoite p.falciparum de recom binaison
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20040096463A1 (en) * 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
WO2002074336A2 (fr) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Vaccin
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
US20030108565A1 (en) 2001-07-10 2003-06-12 Johnson Mark E. Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
JP4592284B2 (ja) 2001-07-27 2010-12-01 カイロン ソチエタ ア レスポンサビリタ リミタータ 髄膜炎菌付着因子
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
CA2860702C (fr) 2001-12-17 2019-02-26 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
WO2003089460A1 (fr) 2002-04-19 2003-10-30 The Governing Council Of The University Of Toronto Methodes et compositions immunologiques pour le traitement de la maladie d'alzheimer
ATE414176T1 (de) 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
JP2006500963A (ja) 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
NZ539509A (en) 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PT1581812E (pt) 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon
BRPI0407032A (pt) 2003-01-29 2006-01-17 Pfizer Prod Inc Vacinas caninas contra bordetella bronchiseptica
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
WO2004067030A2 (fr) 2003-01-30 2004-08-12 Chiron Srl Vaccins injectables contre les multiples serogroupes du meningocoque
DK1613346T3 (da) 2003-04-04 2013-01-07 Pah Usa 15 Llc Mikrofluidiske olie-i-vand-emulsioner og vaccinesammensætninger
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005032584A2 (fr) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Composes
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP1708745B1 (fr) 2003-12-23 2012-04-18 Arbor Vita Corporation Anticorps pour des souches oncogenes du hpv et leurs methodes d'utilisation
AU2005213457A1 (en) 2004-02-05 2005-08-25 The Ohio State University Research Foundation Chimeric VEGF peptides
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
KR20070008625A (ko) * 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
DK1740217T3 (da) 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1766034B1 (fr) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Vecteurs alphavirus pour vaccins contre le virus influenza
EP2497831B1 (fr) 2004-05-25 2014-07-16 Oregon Health and Science University Vaccin contre la Tuberculosis utilisant des vecteurs de vaccin à base de HCMV
CA2565500A1 (fr) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
EP2612679A1 (fr) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
CN102657855B (zh) 2004-09-22 2015-12-09 葛兰素史密丝克莱恩生物有限公司 用于进行抗葡萄球菌接种的免疫原性组合物
US8846051B2 (en) 2004-10-08 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by deoptimization of synonymous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2600898C (fr) 2004-12-07 2016-08-23 Toray Industries, Inc. Nouveau peptide antigene contre le cancer et applications
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
MX291624B (es) 2005-02-18 2011-11-04 Novartis Vaccines & Diagnostic Inmunogenos de escherichia coli uropatogenica.
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006100111A1 (fr) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
JP2008534594A (ja) 2005-03-31 2008-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム クラミジア感染に対するワクチン
CA2607715C (fr) 2005-04-29 2015-11-24 Glaxosmithkline Biologicals S.A. Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
JP5222134B2 (ja) 2005-06-15 2013-06-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Ｈｅｒ−２ペプチド
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
BRPI0613168A2 (pt) 2005-07-01 2010-12-21 Forsyth Dental In Ry For Children Fa molécula de polipeptìdeo isolada; molécula de ácido nucléico isolada; vetor ou plasmìdeo; célula hospedeira; anticorpo; proteìna de fusão; método para estimular uma resposta imunogênica especìfica à tb em um indivìduo ou para prevenir ou reduzir a gravidade de doença causada pela tb; método para monitorar o tratamento da doença causada pela tb em um indivìduo; método de diagnóstico de doença causada pela tb em um indivìduo; método de distinção entre a doença causada pela tb e a imunidade à doença causada pela tb em um indivìduo; método para detecção da infecção por m. tuberculosis em uma amostra biológica; composição; kit para diagnóstico da presença ou da ausência de infecção por m. tuberculosis em uma pessoa; e composição farmacêutica
EP1762575A1 (fr) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
WO2007047749A1 (fr) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Immunisations mucosiques et systemiques avec particules de replicon d’alphavirus
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
CA2630220C (fr) 2005-11-22 2020-10-13 Doris Coit Antigenes de norovirus et de sapovirus
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1981905B1 (fr) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccin contre chlamydia
CA2636566C (fr) 2006-01-17 2018-03-13 Arne Forsgren Nouvelle proteine de haemophilus influenzae a surface exposee (proteine; pe)
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
JP5014413B2 (ja) 2006-03-30 2012-08-29 エンブレックス・インコーポレイテッド 家禽のワクチン接種のための方法及び組成物
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100021424A1 (en) 2006-06-02 2010-01-28 Vincent Brichard Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
ATE450271T1 (de) 2006-06-12 2009-12-15 Glaxosmithkline Biolog Sa Impfstoff
NZ573931A (en) 2006-06-29 2012-03-30 Craig J Venter Inst Inc Polypeptides from neisseria meningitidis
CN105727276A (zh) 2006-07-17 2016-07-06 葛兰素史密丝克莱恩生物有限公司 流感疫苗
AU2007276217B2 (en) 2006-07-18 2013-08-29 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008012538A2 (fr) 2006-07-25 2008-01-31 The Secretary Of State For Defence Souche de vaccin vivant
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2486938T (pt) 2006-09-26 2018-06-12 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
EP2086582B1 (fr) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccin comprenant une emulsion adjuvante huile en l'eau
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
ES2630205T3 (es) * 2006-11-20 2017-08-18 Duecom Uso de partículas que contengan lípidos que comprenden saponínas quillaja para el tratamiento del cáncer
WO2008068631A2 (fr) 2006-12-06 2008-06-12 Novartis Ag Vaccins comprenant un antigène issu de quatre souches du virus grippal
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2008223951B2 (en) 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
DK2136836T3 (en) 2007-04-04 2017-04-10 Infectious Disease Res Inst Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009014565A2 (fr) 2007-04-26 2009-01-29 Ludwig Institute For Cancer Research, Ltd. Procédés pour le diagnostic et le traitement des astrocytomes
TW200914042A (en) 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
CN101848929A (zh) 2007-05-25 2010-09-29 诺华有限公司 肺炎链球菌菌毛抗原
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0815008B8 (pt) 2007-08-02 2021-05-25 Biondvax Pharmaceuticals Ltd vacinas multiméricas com múltiplos epítopos contra influenza
JP2010535504A (ja) 2007-08-03 2010-11-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ クラミジア抗原
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
EP2201131B8 (fr) 2007-09-17 2014-12-10 MDxHealth SA Détection de méthylation améliorée
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2060583A1 (fr) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification des marqueurs associés aux tumeurs pour diagnostic et thérapie
ES2824683T3 (es) 2007-10-25 2021-05-13 Toray Industries Inductor de la respuesta inmunitaria
EP2062594A1 (fr) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Vaccin de la fièvre catarrhale du mouton et compositions immunogènes, procédé d'utilisation et son procédé de production
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2744739A1 (fr) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Antigenes de chlamydia
PT2227483T (pt) 2007-12-19 2017-06-21 Henry M Jackson Found Advancement Military Medicine Inc Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
EP3109258B1 (fr) 2007-12-24 2019-01-23 ID Biomedical Corporation of Quebec Antigènes recombinants du rsv
CA2716212A1 (fr) 2008-02-21 2009-08-27 Novartis Ag Polypeptides fhbp a meningocoques
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
EP2612680B1 (fr) 2008-04-16 2018-05-23 GlaxoSmithKline Biologicals SA Vaccin
EP2285397B1 (fr) 2008-04-18 2017-07-19 The General Hospital Corporation Immunothérapies utilisant des vaccins autoassemblés
WO2009131673A1 (fr) 2008-04-25 2009-10-29 Ludwig Institute For Cancer Research Ltd. Traitement ciblé pour des sujets avec des cancers du sein négatifs au récepteur de l'œstrogène et négatifs au récepteur de la progestérone
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
KR101707569B1 (ko) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
BRPI0912462B1 (pt) 2008-08-05 2022-03-22 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2349209A2 (fr) 2008-09-26 2011-08-03 Nanobio Corporation Compositions thérapeutiques de nanoémulsion et procédés d'utilisation de celles-ci
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2743904A1 (fr) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Compositions de vaccins contre le cancer et leurs methodes d'utilisation
KR20110091560A (ko) 2008-12-03 2011-08-11 프로테아 벡신 테크놀로지스 엘티디. 글루타밀 ｔＲＮＡ 합성효소(ＧｔＳ) 단편들
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
EP2398821B1 (fr) * 2009-02-17 2017-08-30 GlaxoSmithKline Biologicals S.A. Vaccin à virus inactivé contre la dengue, contenant un adjuvant sans aluminium
EP2221063A1 (fr) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Procédé et compositions pour le diagnostic et le traitement du cancer
KR102340685B1 (ko) 2009-02-20 2021-12-17 가니메드 파마슈티칼스 게엠베하 암의 진단 및 치료를 위한 방법 및 조성물
EP2221375A1 (fr) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Procédé et compositions pour le diagnostic et le traitement du cancer
EP2403526B1 (fr) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Antigènes de chlamydia
EA021100B1 (ru) 2009-03-17 2015-04-30 МДхХЭЛС СА Усовершенствованное определение экспрессии генов
JP5830009B2 (ja) 2009-04-14 2015-12-09 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対して免疫化するための組成物
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2249159A1 (fr) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification des marqueurs associés aux tumeurs pour diagnostic et thérapie
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
EP3020412B1 (fr) 2009-06-16 2017-10-11 The Regents of the University of Michigan Vaccins en nanoémulsion
EA201270062A1 (ru) 2009-06-24 2013-02-28 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Вакцина
DK2445526T3 (en) 2009-06-24 2016-06-27 Glaxosmithkline Biologicals Sa Recombinant RSV antigens.
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
US20120164176A1 (en) 2009-07-15 2012-06-28 Kurt Swanson Rsv f protein compositions amd methods for making same
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
KR101425405B1 (ko) 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
EP2281579A1 (fr) 2009-08-05 2011-02-09 BioNTech AG Composition de vaccin comportant un ADN modifié 5'-Cap
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2471801A4 (fr) 2009-08-26 2013-12-04 Rna Inc Glycolipides dérivés de l'acide lipotéichoïque et compositions contenant ces glycolipides
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
US20120283115A1 (en) 2009-08-31 2012-11-08 Ludwig Institute For Cancer Research Ltd. Seromic analysis of ovarian cancer
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
CN102573900B (zh) * 2009-09-10 2017-05-31 梅里亚股份有限公司 包含含有皂苷的佐剂的新疫苗制剂
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
ES2538007T3 (es) 2009-09-16 2015-06-16 Vaxart, Inc. Estrategia de inmunización para prevenir una infección por H1N1
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
WO2011040978A2 (fr) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Epitopes de ny-eso-1 immunodominants restreints par dr52b du cmh, monomères et multimères du cmh de classe ii et leur utilisation
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
EP2493499A1 (fr) 2009-10-27 2012-09-05 Novartis AG Polypeptides fhbp méningococciques modifiés
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2322555A1 (fr) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Anticorps spécifiques pour claudin 6 (CLDN6)
BR112012011143B1 (pt) 2009-11-11 2020-05-19 Ganymed Pharmaceuticals Ag "anticorpos específicos para claudina 6 (cldn6)".
WO2011067758A2 (fr) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
EP2366709A1 (fr) 2010-03-16 2011-09-21 BioNTech AG Vaccination anti-tumeur impliquant une réponse immunitaire humorale contre les protéines endogènes
EP2547695B1 (fr) 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Vaccination anti-tumeur impliquant une réponse immunitaire humorale contre la protéine endogène CLDN18.2
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスｂ１９のウイルス様粒子を生成するための方法
EP2558069A1 (fr) 2010-04-13 2013-02-20 Novartis AG Compositions de benzonapthyridine et leurs utilisations
WO2011149564A1 (fr) 2010-05-28 2011-12-01 Tetris Online, Inc. Infrastructure de jeu informatique asynchrone hybride interactif
KR101609032B1 (ko) 2010-06-04 2016-04-04 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 백신 제제
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
CA2804501C (fr) 2010-07-06 2021-01-26 Novartis Ag Compositions immunogenes derivees d'un norovirus et methodes
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2812153C (fr) 2010-09-20 2020-06-30 Biontech Ag Recepteur des cellules t specifiques des antigenes et epitopes des cellules t
WO2012041669A1 (fr) 2010-09-27 2012-04-05 Crucell Holland B.V. Régime de vaccination de type amorce rappel hétérologue contre la malaria
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
CN103237560B (zh) 2010-10-15 2016-05-11 葛兰素史密丝克莱恩生物有限公司 巨细胞病毒gb抗原
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
ES2859673T3 (es) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
PT3023106T (pt) 2010-12-14 2019-11-04 Glaxosmithkline Biologicals Sa Composição antigénica de micobactéria
WO2012085668A2 (fr) 2010-12-24 2012-06-28 Novartis Ag Composés
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
ES2727836T3 (es) 2011-01-26 2019-10-21 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
AU2012211043B2 (en) 2011-01-27 2017-04-06 Gamma Vaccines Pty Limited Combination vaccines
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012135177A2 (fr) 2011-03-29 2012-10-04 Uab Research Foundation Procédés et compositions permettant d'obtenir une protéine il-10 de cytomégalovirus
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
MX341147B (es) 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Anticuerpos para el tratamiento del cáncer que expresa cldn6.
CA2835644C (fr) 2011-05-13 2021-06-15 Novartis Ag Antigenes de pre-fusion f du vrs
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
WO2012157737A1 (fr) 2011-05-19 2012-11-22 東レ株式会社 Agent d'induction d'immunité
AU2012256756B2 (en) 2011-05-19 2017-06-08 Toray Industries, Inc. Immunity induction agent
SI3892295T1 (sl) 2011-05-24 2023-09-29 BioNTech SE Individualizirana cepiva proti raku
ME03498B (fr) 2011-05-24 2020-04-20 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vaccins individualisés pour le cancer
WO2012159643A1 (fr) 2011-05-24 2012-11-29 Biontech Ag Vaccins individualisés pour le cancer
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
JP2014527398A (ja) 2011-06-21 2014-10-16 オンコファクター コーポレイション がんの療法および診断のための組成物および方法
CA2841047A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions immunogenes et leurs utilisations
CA2840989A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions de combinaisons immunogenes et utilisations de celles-ci
EP2729178A1 (fr) 2011-07-08 2014-05-14 Novartis AG Procédé de ligature de la tyrosine
EP2736921B1 (fr) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
PL2758432T3 (pl) 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2013074501A1 (fr) 2011-11-14 2013-05-23 Crucell Holland B.V. Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
SI2782598T1 (sl) 2011-11-23 2020-12-31 In3Bio Ltd. Rekombinantni proteini in njihove terapevtske uporabe
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
DK2785683T3 (da) 2011-11-30 2020-04-14 Ludwig Inst For Cancer Res Ltd Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013108272A2 (fr) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Vaccin antipaludique ciblant le stade sanguin
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
WO2013134577A2 (fr) 2012-03-08 2013-09-12 Detectogen, Inc. Dosages de détection d'antigène de leishmaniose et vaccins
EP2833900B1 (fr) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Peptides d'inducteur de métalloprotéinase de matrice extracellulaire (emmprin) et anticorps de liaison
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
RU2659149C2 (ru) 2012-08-03 2018-06-28 Инфекшес Дизиз Рисерч Инститьют Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
CA2885625A1 (fr) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Conjugues saccharidiques non lineaires
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
BR112015009229B1 (pt) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
WO2014074785A1 (fr) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Procédés de prédiction de l'issue et du traitement du cancer du sein
WO2014082729A1 (fr) 2012-11-28 2014-06-05 Biontech Ag Vaccins individualisés contre le cancer
SI2925355T1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals S.A. Antigens and combinations of Pseudomonas antigens
SI2928489T1 (sl) 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
UY35418A (es) 2013-03-15 2014-10-31 Glaxosmithkline Biolog Sa Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
IL286537B (en) 2013-03-15 2022-07-01 In3Bio Ltd Synthetic proteins that assemble themselves
ES2728865T3 (es) 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
MX365957B (es) 2013-06-26 2019-06-20 Univ North Carolina Chapel Hill Métodos y composiciones para vacunas del virus del dengue.
EP3777882A1 (fr) 2013-07-30 2021-02-17 BioNTech SE Antigenes de tumeur pour determiner la therapie du cancer
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
EP2870974A1 (fr) 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
WO2015071763A2 (fr) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
WO2015077442A2 (fr) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Immunogènes de pollen de graminée ainsi que procédés et utilisations pour la modulation de la réponse immunitaire
US20160287696A1 (en) 2013-11-20 2016-10-06 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
PT3089754T (pt) 2013-12-31 2021-07-23 Infectious Disease Res Inst Formulações de vacina de dose única
EP3107568B1 (fr) 2014-02-20 2024-03-27 Vaxart, Inc. Formulations pour administration dans l'intestin grêle
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (fr) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides dérivés de phl p, procédés et utilisations de ces derniers pour moduler une réponse immunitaire
MX2016012168A (es) 2014-03-25 2017-04-25 The Government Of The Us Secretary Of The Army Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina.
MX2016012538A (es) 2014-03-26 2016-12-14 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015189425A1 (fr) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Combinaisons immunogènes
PL3160500T3 (pl) 2014-06-25 2020-02-28 Glaxosmithkline Biologicals S.A. Immunogenna kompozycja clostridium difficile
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
EP4112076A1 (fr) 2014-10-10 2023-01-04 The Regents of The University of Michigan Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
WO2016062323A1 (fr) 2014-10-20 2016-04-28 Biontech Ag Methodes et compositions de diagnostic et de traitement du cancer
SG11201703366RA (en) 2014-11-02 2017-05-30 Univ North Carolina Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
WO2016128060A1 (fr) 2015-02-12 2016-08-18 Biontech Ag Prédiction des épitopes de lymphocytes t utiles pour la vaccination
WO2016134300A1 (fr) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Méthodes et compositions permettant d'utiliser la chlamydia atténuée en tant que vaccin et vecteur
US10813993B2 (en) 2015-03-03 2020-10-27 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
EP4226937A3 (fr) 2015-03-05 2023-09-27 Northwestern University Virus non neuro-invasifs et leurs utilisations
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
CN116603058A (zh) 2015-03-26 2023-08-18 Gpn疫苗有限公司 链球菌疫苗
CA2986961C (fr) 2015-05-26 2023-07-25 Ohio State Innovation Foundation Strategie vaccinale a base de nanoparticules contre le virus de la grippe porcine
US11433146B2 (en) 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
EP3138579A1 (fr) 2015-09-05 2017-03-08 Biomay Ag Protéine de fusion pour son utilisation dans le traitement d'une infection par le virus de l'hépatite b
EP3365006A1 (fr) * 2015-10-19 2018-08-29 Cadila Healthcare Limited Nouvel adjuvant et composition vaccinale le contenant
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522132D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Vaccine
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
JP2019511246A (ja) 2016-03-10 2019-04-25 アペリシス， インコーポレイテッド 改変ｈｓｐ７０ドメインを有する抗原結合融合タンパク質
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
EP3430039A1 (fr) 2016-03-14 2019-01-23 Universitetet I Oslo Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
WO2017167768A1 (fr) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Nouvelle composition vaccinale
MX2018011113A (es) 2016-03-28 2018-11-09 Toray Industries Agente inductor de inmunidad.
WO2017201390A1 (fr) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Nouvelles compositions adjuvantes
WO2017205225A2 (fr) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions et méthodes de traitement de la tuberculose secondaire et des infections à mycobacterium non tuberculeuses
EP3471761A2 (fr) 2016-06-21 2019-04-24 University Of Oslo Fragments de vaccin de liaison à hla et leurs utilisations
DK3488443T3 (da) 2016-07-20 2021-09-27 BioNTech SE Udvælgelse af neoepitoper som sygdomsspecifikke mål for terapi med øget virkning
EP3504230A1 (fr) 2016-08-23 2019-07-03 GlaxoSmithKline Biologicals SA Peptides de fusion avec des antigènes liés à des fragments courts de chaîne invariante (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
MX2019003035A (es) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
EP3295956A1 (fr) 2016-09-20 2018-03-21 Biomay Ag Construction de polypeptide comprenant des fragments d'allergenes
WO2018060288A1 (fr) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions et méthodes de traitement d'une infection par hpv persistante
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018077385A1 (fr) 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Détermination de doses d'agents immunothérapeutiques
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3043790A1 (fr) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Nouvelles proteines f du vrs de pre-fusion recombinant et leurs utilisations
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
WO2018178264A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et méthode de traitement
CN110945022B (zh) 2017-04-19 2024-04-05 生物医学研究所 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
SG10202108075YA (en) * 2017-04-25 2021-09-29 Adjuvance Technologies Inc Triterpene saponin analogues
EP3615061A1 (fr) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87413B1 (en) * 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CN107375921B (zh) * 2017-06-12 2019-10-29 商丘美兰生物工程有限公司 一种甘草皂苷脂质体免疫佐剂及其制备方法
CA3066020A1 (fr) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Methode de traitement
CN111246878A (zh) 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
WO2019035963A1 (fr) 2017-08-16 2019-02-21 Ohio State Innovation Foundation Compositions à nanoparticules pour vaccins contre les salmonelles
US20220118076A1 (en) 2017-09-07 2022-04-21 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
CA3078223A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procedes d'utilisation
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
JP2021512950A (ja) 2018-02-02 2021-05-20 エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． 新規なワクチンの免疫補助剤
US20210363172A1 (en) 2018-03-15 2021-11-25 Biontech Rna Pharmaceuticals Gmbh 5'-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing rna, expressing proteins in therapy
EP3569612A1 (fr) 2018-05-18 2019-11-20 Biomay Ag Traitement et prévention d'allergies aux acariens
WO2019239311A1 (fr) 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Polynucléotides et polypeptides d'adénovirus
EP3581201A1 (fr) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptides et leurs utilisations
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
US20210220462A1 (en) 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020055503A1 (fr) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Adjuvant vaccinal à base de nanoparticules, et méthodes d'utilisation associées
WO2020115171A1 (fr) 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Compositions immunogènes
EP3897846A1 (fr) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Méthodes d'induction d'une réponse immunitaire
EP3914708A1 (fr) 2019-01-24 2021-12-01 Massachusetts Institute Of Technology Plateforme de nanostructure d'acide nucléique pour présentation d'antigène et formulations de vaccin formées grâce à son utilisation
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
CA3144845A1 (fr) 2019-06-25 2020-12-30 In3Bio Ltd. Proteines synthetiques chimeriques stabilisees et leurs utilisations therapeutiques
US20220273789A1 (en) 2019-07-21 2022-09-01 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
AU2020325645A1 (en) 2019-08-05 2022-02-17 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
US20220362368A1 (en) 2019-10-02 2022-11-17 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
EP4058581A1 (fr) 2019-11-15 2022-09-21 Infectious Disease Research Institute Agoniste de rig-i et formulation d'adjuvant pour le traitement de tumeurs
WO2021122551A1 (fr) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa Antigènes de s. aureus et compositions associées
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用
EP4114848A4 (fr) 2020-02-26 2024-04-03 Versitech Limited Vaccins à base de pd-1 dirigés contre une infection à coronavirus
WO2021245611A1 (fr) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Protéines modifiées de spicule de coronavirus bêta
WO2022029024A1 (fr) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa PROTÉINE FUSOBACTERIUM ADHÉSINE A (FadA) DE FUSOBACTERIUM NUCLEATUM TRONQUÉE ET COMPOSITIONS IMMUNOGÈNES À BASE DE CELLE-CI
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
US20230416309A1 (en) 2020-10-23 2023-12-28 Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji Fusion protein and application thereof
CN116847830A (zh) 2020-10-28 2023-10-03 赛诺菲巴斯德有限公司 含tlr4激动剂的脂质体、其制备和用途
CA3202549A1 (fr) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Nouveaux antigenes
AR124604A1 (es) 2021-01-12 2023-04-12 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con los mismos y uso de los mismos
EP4032547A1 (fr) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Fragments dérivés du hsv 1 fce pour le traitement du hsv
WO2022175423A1 (fr) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Composition immunogène, utilisation et procédés
WO2022192038A1 (fr) 2021-03-12 2022-09-15 Northwestern University Vaccins antiviraux utilisant des acides nucléiques sphériques
CN117320745A (zh) 2021-03-30 2023-12-29 维拉瓦克斯股份公司 Sars-cov-2亚单位疫苗
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
TW202304504A (zh) 2021-04-01 2023-02-01 美商詹森藥物公司 大腸桿菌ｏ１８生物軛合物之生產
BR112023027401A2 (pt) 2021-06-28 2024-03-12 Glaxosmithkline Biologicals Sa Antígenos do vírus influenza
CN118019754A (zh) 2021-09-23 2024-05-10 维拉瓦克斯股份公司 诱导pres特异性中和抗体的hbv疫苗
WO2023079528A1 (fr) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions appropriées pour une utilisation dans un procédé pour déclencher une immunité protectrice croisée contre des coronavirus
WO2023079529A1 (fr) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions d'immunisation de rappel de protéine de refocalisation et leurs méthodes d'utilisation
WO2023114727A1 (fr) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Système de vaccin du bactériophage lambda
WO2023114570A1 (fr) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions et méthodes pour obtenir des réponses durables des centres germinatifs à une sensibilisation active
WO2023144665A1 (fr) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus humain modifiées
WO2023154960A1 (fr) 2022-02-14 2023-08-17 University Of Georgia Research Foundation, Inc. Compositions de vaccins pan-pneumovirus et leurs méthodes d'utilisation
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué
WO2024130009A1 (fr) 2022-12-14 2024-06-20 Yale University Compositions et leurs procédés d'utilisation pour le traitement de cancers entraînés par un virus
WO2024133160A1 (fr) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Compositions pour le traitement de l'hépatite b
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE69027112T2 (de) * 1989-01-23 1997-01-09 Auspharm International Ltd 4Th Impfstoffzusammensetzung
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
DK0671948T3 (da) * 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
CA2156525A1 (fr) * 1993-02-19 1994-09-01 Susan Dillon Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
DK0705109T4 (da) * 1993-05-25 2004-05-10 Wyeth Corp Adjuvanser til vacciner mod respiratorisk syncytialvirus
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9718901D0 (en) † 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
ES2293708T3 (es) 2008-03-16
MX9708226A (es) 1998-06-30
CN1289065C (zh) 2006-12-13
HK1025244A1 (en) 2000-11-10
DE69637254T2 (de) 2008-06-19
ATE186842T1 (de) 1999-12-15
CN1515245A (zh) 2004-07-28
SK144297A3 (en) 1998-05-06
UA56132C2 (uk) 2003-05-15
DK0822831T4 (da) 2006-12-27
EP0955059B1 (fr) 2007-09-19
SI0822831T2 (sl) 2006-12-31
CN1248737C (zh) 2006-04-05
JPH11504020A (ja) 1999-04-06
AR001686A1 (es) 1997-11-26
IL118004A0 (en) 1996-08-04
KR100463372B1 (ko) 2005-02-28
AU699213B2 (en) 1998-11-26
GR3031912T3 (en) 2000-02-29
CZ337997A3 (cs) 1998-03-18
BR9608199A (pt) 1999-05-18
KR19990008003A (ko) 1999-01-25
PL184061B1 (pl) 2002-08-30
NO974859L (no) 1997-10-21
BR9608199B1 (pt) 2009-05-05
CN1111071C (zh) 2003-06-11
SK282017B6 (sk) 2001-10-08
SI0822831T1 (en) 2000-02-29
CN1480214A (zh) 2004-03-10
EP0955059A2 (fr) 1999-11-10
DK0822831T3 (da) 2000-05-01
EA199700272A1 (ru) 1998-04-30
EP0822831B1 (fr) 1999-11-24
WO1996033739A1 (fr) 1996-10-31
PL322968A1 (en) 1998-03-02
DE69605296T3 (de) 2007-02-15
TW515715B (en) 2003-01-01
BG101995A (en) 1998-11-30
AP771A (en) 1999-10-07
CN1182370A (zh) 1998-05-20
EP0822831A1 (fr) 1998-02-11
HUP9801560A3 (en) 1999-07-28
HU227944B1 (en) 2012-06-28
MY134811A (en) 2007-12-31
AU693022B2 (en) 1998-06-18
CA2217178A1 (fr) 1996-10-31
AP9701123A0 (en) 1997-10-31
PT955059E (pt) 2007-11-27
MA23850A1 (fr) 1996-12-31
BG63491B1 (bg) 2002-03-29
SA96170297B1 (ar) 2005-11-15
CA2217178C (fr) 2009-09-29
DE69605296T2 (de) 2000-05-18
EP0884056A1 (fr) 1998-12-16
EA000839B1 (ru) 2000-04-24
AU5334596A (en) 1996-11-18
DZ2026A1 (fr) 2002-07-21
DE69637254D1 (de) 2007-10-31
DE69605296D1 (de) 1999-12-30
CY2588B2 (en) 2009-11-04
ATE373487T1 (de) 2007-10-15
HK1009086A1 (en) 1999-05-28
EP0822831B2 (fr) 2006-08-23
AU6987398A (en) 1998-07-23
IL118004A (en) 1999-11-30
HUP9801560A1 (hu) 1998-10-28
RO119068B1 (ro) 2004-03-30
CZ296216B6 (cs) 2006-02-15
ES2140076T3 (es) 2000-02-16
EP0955059A3 (fr) 2000-07-12
NZ305365A (en) 1999-05-28
JP3901731B2 (ja) 2007-04-04
SI0955059T1 (sl) 2008-02-29
NO322190B1 (no) 2006-08-28
NO974859D0 (no) 1997-10-21
ES2140076T5 (es) 2007-04-16
OA10629A (en) 2002-09-16
TR199701252T1 (xx) 1998-03-21

Similar Documents

Publication Publication Date Title
DK0822831T3 (da) Vacciner indeholdende en saponin og en sterol
NO961425D0 (no) 1N-alkyl-N-arylpyrimidinaminer og derivater derav
DE69523670D1 (de) Anzeigeverfahren und -gerät
DK0761152T3 (da) Shaker og blender
DK0870148T3 (da) Hurtig-til-/fra-kobling og fremgangsmåde og indretning til samling deraf
DE69628873D1 (de) Ausrichtgerät und -verfahren
DE69415632D1 (de) Filamentwickelverfahren und -vorrichtung
NO952763L (no) Ekspresjonssystemer under anvendelse av autolyserende fusjonsproteiner og et nytt reduserende polypepid
BR9602121A (pt) Poliuretano-poliuréias e sua utilização
NO960913L (no) Eske og emne for en eske
DK564189D0 (da) Insecticidt praeparat og insecticid aerosol
NO974932D0 (no) Pesticidpreparater og fremgangsmåte for fremstilling derav
IE880582L (en) Framing and display device
NO975578D0 (no) Vinylsulfosyder og en fremgangsmåte for fremstilling derav
IL116541A0 (en) Helicobacter proteins and vaccines
NO975114D0 (no) Skap og sammenstilling
KR950013575U (ko) 펀치(punch)와 호치키스(hotch-kiss)가 일체형으로 된 기구
GB9519277D0 (en) Toy figure and toy figure actuating device
NO934392D0 (no) Rullgardin og beslag for rullgardin